<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S1906 IS: Orphan Drug Fairness Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-07-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>1st Session</session>
		<legis-num>S. 1906</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20150730">July 30, 2015</action-date>
			<action-desc><sponsor name-id="S306">Mr. Menendez</sponsor> (for himself and <cosponsor name-id="S266">Mr. Crapo</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To clarify the exclusion of orphan drug sales from the calculation of the annual fee on branded
			 prescription pharmaceutical manufacturers and importers, and for other
			 purposes.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Orphan Drug Fairness Act</short-title></quote>.</text>
		</section><section id="id25334B455A4C4C338259D0CCA010451F"><enum>2.</enum><header>Exclusion of orphan drug sales</header>
 <subsection id="id23780C6D51D34D2CB7551352851D228E"><enum>(a)</enum><header>In general</header><text>Paragraph (3) of section 9008(e) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/26/4001">26 U.S.C. 4001</external-xref> note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="id39E82CEFEE2F43DC8E6D8ACB02B3F4D3" style="OLC">
 <paragraph id="id2518fff9ff944fd3bb7e52e73c491dac"><enum>(3)</enum><header>Exclusion of orphan drug sales</header><text>The term <term>branded prescription drug sales</term> shall not include sales of any drug or biological product with respect to which a credit was allowable for any taxable year under <external-xref legal-doc="usc" parsable-cite="usc/26/45C">section 45C</external-xref> of the Internal Revenue Code of 1986, regardless of whether such credit was claimed and received. The preceding sentence shall not apply with respect to any such drug or biological product after the date on which such drug or biological product is approved by the Food and Drug Administration for marketing for any indication other than the treatment of the rare disease or condition with respect to which such credit was allowable.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" display-inline="no-display-inline" id="id68D07A7E148D4484997EC12AF8EAE6EA"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall take effect as if included in section 9008 of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/26/4001">26 U.S.C. 4001</external-xref> note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>).</text>
			</subsection></section></legis-body>
</bill>


